Alzheon identifies MOA for AD candidate

In a paper published in CNS Drugs, researchers from Alzheon Inc. (Framingham, Mass.) identified the mechanism of action for tramiprosate, the active agent in its Alzheimer's disease candidate ALZ-801. The paper showed that the compound inhibits beta amyloid oligomer formation through an enveloping mechanism.

Authors also included researchers from Schrödinger LLC, University of Gothenburg, Icahn School of Medicine at Mount Sinai and the Alzheimer’s Drug Discovery Foundation...